TAL reported a solid earnings beat for 1QFY26. Revenue grew 39% yoy to US$575m for 1QFY26, in line with our and consensus estimates. Gross profit rose 47% yoy to US$315m, with gross margin expanding 3ppt yoy to 55%. Non-GAAP net profit beat expectations and came in at US$42m vs the street’s estimate of US$31m. Non-GAAP net margin remained flattish yoy at 7% despite stepped-up marketing efforts for AI learning devices. Maintain BUY with an unchanged target price of US$14.00.
Levelling The Field: Tariff Normalisation Reinforces Malaysia’s Role As An Onshoring Destination At last, the White House administration has updated the reciprocal tariff schedule established under the earlier 2025 trade policy, based on fresh assessments and evolving negotiations with trading partners. Accordingly, the modifications reflect outcomes of bilateral talks and align tariff changes with ongoing partnerships to address perceived imbalances and encourage investments and trade reforms. ...
Loans Growth Tapers Amid Caution Loan growth softened to 5.1% in Jun 25 (May 25: +5.3%), driven by weaker business lending. Loan applications, particularly from businesses, also declined, likely reflecting a cautious stance amid tariff uncertainties. We maintain our 2025 loan growth forecast at 5-6%, implying a 1.4x loan-to-GDP multiplier, consistent with the historical 1.0x-1.7x range. Maintain MARKET WEIGHT, with a preference for defensive names like Hong Leong Bank and Public Bank.
13MP: Elevation, Empowerment And Reformation 13MP aims to transform Malaysia into a high-tech, high value-added economy, anchored on balanced domestic development and deeper global integration that uplifts the Rakyat. While market response has remained subdued amid lingering macro uncertainties, we anticipate a market recovery in 2H25, driven by renewed risk-on sentiment following greater tariff clarity. A more favourable outcome could catalyse a rebound in selective, beaten-down export-oriented...
FEHT focuses on preserving occupancy. Management tactically reduced room rates for its hotels to stabilise occupancy at 79.8% and RevPAR at S$131 in 2Q25. The acquisition of FPSN was completed on 25 Apr 25 and contributed revenue of S$1.6m. Revenue from its commercial premises grew 6.4% yoy in 1H25. FEHT’s low aggregate leverage of 31.2% provides defensive strength and option to expand via acquisition in 2026. Maintain BUY. Target price: S$0.81.
KEY HIGHLIGHTS Sector REITs: S-REITs monthly update (Jul 25). Results Far East Hospitality Trust (FEHT SP/BUY/S$0.60/Target: S$0.81): 1H25: Maiden contribution from Japan; growth from commercial premises. Keppel (KEP SP/BUY/S$8.47/Target: S$9.51): 1H25: Strong growth, steady dividends, and asset-light transformation in motion. Maintain BUY. Seatrium (STM SP/BUY/S$2.27/Target: S$2.96): 1H25: Robust revenue growth with continued gross margin expansion. Maintain BUY with target price of S$2.96. S...
KEY HIGHLIGHTS Economics PMI July's manufacturing PMI slipped to 49.3 (-0.4pt mom), while non-manufacturing PMI dropped to 50.1 (-0.4pt mom), as construction activity eased to 50.6 (-2.2pt mom). Slowing demand and rising input costs are slowing the recovery and affecting both large (-0.9pt mom) and small enterprises (-0.9pt mom). Nevertheless, business expectations have improved and should see a further lift from targeted anti-involution measures. Sector Automobile China’s PV insurance regis...
GREATER CHINA Economics PMI Rebound falters, weighed down by weaker construction and input cost pressures. Sector Automobile Weekly: PV sales pressured by anti-involution initiatives. Maintain MARKET WEIGHT on the sector. Top BUYs: CATL, Geely and Tuopu. Results Budweiser APAC (1876 HK/BUY/HK$8.26/Target: HK$12.00) ...
Singapore is a haven due to its fiscal discipline and the lowest reciprocal tariff of 10%. The flight to safety is evidenced by low 10-year Singapore government bond yield of 2.1% and 3-month compounded SORA of 1.9%. Maintain OVERWEIGHT. BUY suburban retail REITs CICT (Target: S$2.72), FCT (Target: S$3.07) and LREIT (Target: S$0.76) and data centre REITs DCREIT (Target: US$0.88) and KDCREIT (Target: S$2.69). We also like CLAR (Target: S$4.02).
EDU’s 4QFY25 results beat expectations. Revenue grew 9% yoy to US$1,243m, 5% better than our and consensus forecasts. Non-GAAP net profit came in at US$7m, beating our and consensus estimates, while net margin expanded 2ppt yoy to 8% for 4QFY25. EDU expects 1QFY26 revenue to rise 2-5% yoy to US$1,464.1m-1,507.2m, 5- 8ppt below expectations. Maintain BUY with a lower target price of US$55.00 (HK$43.00).
All the healthcare stocks under our coverage exhibited a positive performance from 16-30 July. Due to expectations of strong results for 1H25, CRDMO companies were the top performers, with share prices surging by 22-34%. Supported by major BD/M&A deals, MicroPort, Sino Biopharm and Hengui Medicines also saw their stock prices rise significantly by 65.3%, 16.8% and 13.0%, respectively.
2Q25: CIMB Niaga Results: Subdued Outcome CIMB Niaga reported 2Q25 net profit of Rp1,650m (-8.6% qoq, -4.4% yoy) bringing 1H25 earnings to Rp3,455 (+1.4% yoy). CIMB Niaga’s. Earnings were in line, with 1H25 net profit accounting for 52% of both our and consensus full-year forecasts. Earnings rose 1.4% yoy, supported by lower provisions as net credit cost declined 24bps to 65bps. However, this was partially offset by a 25bps compression in NIM to 3.96%, negative operating jaws, and softer non-int...
KEY HIGHLIGHTS Sector Healthcare All the healthcare stocks under our coverage exhibited a positive performance from 16-30 July. Due to expectations of strong results for 1H25, CRDMO companies were the top performers, with share prices surging by 22-34%. Supported by major BD/M&A deals, MicroPort, Sino Biopharm and Hengui Medicines also saw their stock prices rise significantly by 65.3%, 16.8% and 13.0%, respectively. Results Contemporary Amperex Technology (300750 CH/BUY/Rmb277.09 /Target: R...
With Petronas/Eni Biorefinery, Pengerang Catalysts For Storage To Come The US$330m take-or-pay contract awarded to DLG on new 0.3m cu m capacity in PT2SB for biofuels is expected to commence operations in 2H28 for 25 years. The DCF accretion may appear small (2% to SOP), but the sheer size of the capacity allocated for energy transition bodes well for DLG’s ESG, and there are more storage catalysts to come in Pengerang. Concurrently, Vopak’s 1H25 results and upgraded outlook support storage deve...
KEY HIGHLIGHTS Results Keppel REIT (KREIT SP/BUY/S$0.97/Target: S$1.18): 1H25: Benefitting from Singapore growing in stature as a regional hub. Oiltek International (OTEK SP/BUY/S$0.89/Target: S$1.05): 1H25: Record-high earnings and outlook remains positive; maintain BUY. TRADERS’ CORNER First Resources (FR SP): Trading BUY Keppel DC REIT (KDCREIT SP): Trading BUY
GREATER CHINA Sector Healthcare Bi-Weekly: Expecting strong 1H25 results. Maintain OVERWEIGHT. Results Contemporary Amperex Technology (300750 CH/BUY/Rmb277.09 /Target: Rmb390.00) 2Q25: Earnings in line, with margins hitting record-high levels. Maintain A-share at BUY. Downgrade H-share to HOLD. New Oriental Education & Technology Group (EDU US/BUY/US$44.37/Target: US$55.00) ...
KREIT achieved positive rental reversion of 12.3% in 1H25 and targets to achieve double-digit reversion for the full year. It has substantially backfilled vacancies at OFC in Singapore and 255 George Street in Sydney. NPI growth was particularly strong at 13.4% yoy for Australia. KREIT benefits as Singapore strengthens its positioning as a financial and regional hub. It provides a 2026 yield of 6.9% (CICT: 5.1%, Suntec: 5.0%) and P/NAV is at 0.80x. Maintain BUY. Target price: S$1.18.
2Q25: ADV Remains Muted Amid Cautious Sentiment Bursa’s 2Q25 results were broadly in line with expectations, with both yoy and qoq earnings impacted by softer ADV. While current trading volumes remain subdued, they are in line with our projections. We maintain our HOLD rating with a higher target price of RM7.87 (from RM7.29) as we roll forward our valuation to 2026, factoring in a modest ADV recovery supported by the anticipated resumption of Fed rate cuts and a gradual return of risk appetite.
Beating market estimates, WuXi AppTec’s total revenue and adjusted earnings expanded by 20.6% yoy and 44.4% yoy respectively in 1H25. Driven by the strong expansion of the TIDES business, WuXi AppTec raised its revenue growth target to 13- 17% yoy in 2025. We believe surging investment in the biopharmaceutical segment will boost CRDMO service demand for WuXi AppTec in the next few years. Upgrade to BUY with a higher target price of HK$146.00 to reflect a stronger earnings growth outlook.
WAIC 2025 was held in Shanghai on 26-28 July under the theme "Intelligent Horizons, Shared Future". The focus of WAIC this year shifted from LLM to the next frontier – AI applications and AI agents. As AI capabilities extend from the cloud to edge devices, a transformative evolution in human-AI interaction is underway, characterised by more tangible, embodied forms and empathetic voice interfaces. Maintain MARKET WEIGHT.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.